Colorectal cancer (CRC) remains a global health crisis, claiming over 900,000 lives annually and ranking as the second leading cause of cancer-related deaths worldwide. In 2026, the World Health Organization (WHO) reports that only 15% of CRC cases are detected in the early stages, when the 5-year survival rate exceeds 90%. For most patients, diagnosis comes too late—when the cancer has already spread, and survival plummets to less than 10%. This stark disparity underscores a critical need for accessible, early screening tools. Enter Sejoy FOB test strips, a revolutionary fecal occult blood test that is breaking down barriers to CRC detection and saving lives through simplicity, accuracy, and affordability.
Fecal occult blood testing (FOBT) works by detecting trace amounts of blood in stool, an early sign of colorectal polyps or cancer. Traditional FOBT methods, such as the guaiac-based test, require strict dietary restrictions and often produce false results, leading to low patient compliance. Sejoy FOB test strips address these limitations with an immunochemical design that targets human hemoglobin, eliminating the need for dietary changes and reducing false positives by 30% compared to conventional tests. The strips are easy to use: patients collect a small stool sample at home, apply it to the strip, and read results in 10 minutes. No laboratory equipment or specialized training is required, making them ideal for use in primary care clinics, community health centers, and even remote areas with limited medical resources.
In China, where CRC is the second most common cancer with 517,000 new cases annually, Sejoy FOB test strips are playing a pivotal role in national screening programs. In 2026, the city of Xuzhou launched a free CRC screening initiative for 72,000 residents aged 45–74, using Sejoy FOB test strips as the primary screening tool. Within three months, 15% of participants tested positive, and 3,200 individuals were referred for colonoscopies. Of those, 120 early-stage CRC cases were detected, along with 450 precancerous polyps—all of which were successfully removed through minimally invasive procedures. Dr. Li Guofeng, a colorectal surgeon at Xuzhou First People’s Hospital, emphasizes: “Sejoy’s strips are a game-changer. They turn screening from a daunting hospital visit into a simple home test, encouraging more people to get checked early when treatment is most effective.”
Beyond China, Sejoy FOB test strips are making inroads in low- and middle-income countries where CRC screening rates are as low as 5%. In India, where 150,000 people die from CRC each year, non-profit organizations are distributing Sejoy FOB test strips to rural communities through mobile health clinics. The strips have enabled community health workers to screen 10,000 people in 2026 alone, identifying 800 high-risk individuals who would have otherwise gone undiagnosed. “In regions where colonoscopies are rare and expensive, Sejoy’s strips provide a lifeline,” says Dr. Priya Mehta, a public health researcher at the Tata Memorial Centre. “They allow us to triage patients efficiently, focusing resources on those who need immediate care.” What truly sets Sejoy FOB test kits apart is their commitment to equity. Priced cheaper than competing immunochemical FOBT products, making large-scale screening feasible for governments and non-profits.
As we mark World Cancer Day in 2026, the message is clear: early detection saves lives. Sejoy FOB test strips are not just a diagnostic tool; they are a catalyst for change in global cancer care. By making CRC screening accessible, affordable, and user-friendly, Sejoy is empowering individuals to take control of their health and helping healthcare systems shift from treating late-stage cancer to preventing it altogether. In the fight against colorectal cancer, every test strip is a step toward a future where no one dies from a preventable disease.
Post time: Aug-01-2026